11th European AIDS Conference (EACS), Madrid, October 2007
1 Diminished susceptibility to didanosine due to 184I/Vand thymidine analog mutations in isolates without major IAS-USA didanosine-specific and cross-resistant mutations.
J Kjær, A Cozzi-Lepri, Z Fox, and JD Lundgren
Poster P3.2/04 as pdf file 97 kb
2 Concordance between genotypic interpretation systems for predicting resistance to tipranavir/r and darunavir/r: results from the EuroSIDA study. Z Fox, A Cozzi-Lepri, B Clotet, J Kjaer, AN Phillips and JD Lundgren for the EuroSIDA study group
Poster P3.4/02 as pdf file 133 kb
3 Predicting the CD4 slope in patients starting cART after 1 January 1999
JD Lundgren, J Gatell, JR Bogner, K Lacombe, M Murphy, A Wiercinska-Drapalo, P Reiss, A Lazzarin, AN Phillips, A Mocroft for the EuroSIDA study group
Poster P6.11/02/BPD as pdf file 169 kb
4 Virological response to nucleos(t)ide analogues backbones initiated after virological
failure on thymidine analogues-containing treatments. A Cozzi-Lepri, AN Phillips, B Clotet, C Katlama, A Castagna, A Karlsson, B Ledergerber, B Knysz, K Zilmer, O Kirk and JD Lundgren for the EuroSIDA study group
Poster P7.4/01 as pdf file 94 kb
5 Incidence of pancreatitis amongst HIV-positive individuals, and the association with triglycerides and antiretroviral use. CJ Smith, A Mocroft, CH Olsen, F Antunes, S Staszewski, P Domingo, J Weber, E Vinogradova, H Sambattakou, JP Viard, JD Lundgren and the EuroSIDA Study Group
Poster P9.10/02 as pdf file 92 kb
6 The EuroSIDA risk score : Separate prediction for AIDS or death. JD Lundgren, B Ledergerber, B Gazzard, D Banhegyi, M Mokras, D Turner, P Domingo, G Fatkenheuer, O Kirk, A Mocroft for the EuroSIDA study group
Poster P18.4/01 as pdf file 199 kb
1 Does diabetes mellitus (DM) confer a risk of coronary heart disease (CHD) equivalent to that of prior CHD in HIV-positive individuals? S Worm, S de Wit, R Weber, C Sabin, P Reiss, W El-Sadr, A D´arminio Monforte, O Kirk, E Fontas, F Dabis, M Law, J Lundgren, N Friis-Møller for the D:A:D Study group
Abstract No. PS2/6 slides
2 Does Hepatitis C virus (HCV) genotype or viral load predict the risk of all-cause mortality of HIV/HCV coinfection? JK Rockstroh, A Mocroft, P Reiss, A D`Arminio Monteforte, M Beniowski, C Pradier, K Zilmer, M Losso, O Kirk, L Peters, B Kupfer, V Soriano on behalf of the EuroSIDA Study Group
Abstract No. PS8/2 slides
3 Epidemiological and virological characteristics of chronic hepatitis C (HCV) within the EuroSIDA observational cohort. V Soriano, A Mocroft, B Ledergerber, B Knysz, S Chaplinskas, L Peters, A Karlsson, C Katlama, M Vogel, J Rockstroh, JD Lundgren for the EuroSIDA study group.
Abstract No. PS8/1 slides
4th IAS Conference on HIV Pathogenisis, Treatment and Prevention, Sydney, July 2007
1 Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic therapy arm of the SMART study. G Dore, V Soriano, J Neuhaus, L Peters, M Puoti, J Rockstroh, M Klein, E Tedaldi, A Mocroft, B Clotet, JD Lundgren; For the SMART study group and INSIGHT
2 Opportunistic disease and mortality in patients co-infected with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) in the SMART (Strategic Management of Antiretroviral Therapy) study. E Tedaldi, M Puoti, J Neuhaus, L Peters, J Rockstroh, M Klein, G Dore, A Mocroft, V Soriano, B Clotet, JD Lundgren; For the SMART study group and INSIGHT
9th Intl Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney July 2007
1 Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, A D‘Arminio Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren and N Friis-Møller on behalf of the D:A:D study group
Abstract No 0-09
XVI International HIV Drug Resistance Workshop, Barbados, June 2007
1 Prediction of phenotypic susceptibility to the three major HIV drug classes from physiochemical properties of the primary enzymatic structure using artificial neural networks (ANNs). J Kjær, L Høj, Z Fox and JD Lundgren
Poster as pdf file 585 kb
2 Association between Resistance and CD4 Count Change in Patients on ART with Ongoing Viraemia. ZV Fox, AM Geretti, B Clotet, A Cozzi-Lepri, T Hill, H Green, CA Sabin, B Ledergerber, JD Lundgren and AN Phillips for the UK Collaborative Group on HIV Drug Resistance, EuroSIDA and UK CHIC Studies
Poster as pdf file 153 kb
3 Rate of accumulation of thymidine analogue mutations in patients left on virologically failing regimens containing zidovudine or stavudine. A Cozzi-Lepri, AN Phillips, J Martinez-Picado, A d’Arminio Monforte, C Katlama, A-B Eg Hansen, A Horban, J Bruun, B Clotet and J Lundgren for the EuroSIDA study group
Poster as pdf file 86 kb
4 Proof-of-Principle Evaluation of Predictive Performance for Therapy Outcome of Baseline Estimated Fitness and Genetic Barrier towards Resistance in a Clinical Cohort of HIV-1 Treated Patients. K Deforche, A Cozzi-Lepri, K Theys, B Clotet, R Camacho, J Kjaer, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren and A-M Vandamme for the EuroSIDA study Group.
Poster as pdf file 155kb
5th European HIV Drug Resistance Workshop, Cascais, March, 2007
1 Prediction of phenotypic susceptibility to seven protease inhibitors from chemical and structural descriptors of the protease gene’s amino acid sequence using artificial neural networks. J Kjær, L Høj, Z Fox and JD Lundgren
Poster as pdf file 738 kb
14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007
1 HIV-induced immunodeficiency and risk of fatal AIDS-defining and Non-AIDS-defining malignancies: Results from the D:A:D Study Group. A D´Arminio Monforte, D Abrams C Pradier R Weber, F Bonnet, S De Wit, N Friis-Møller, A Phillips, C Sabin, JD Lundgren, and the D:A:D Study Group.
Abstract No. 84
1 Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: The D:A:D CHD risk equation. N Friis-Møller, R Thiébaut, P Reiss, W El-Sadr, R Weber, A D´Arminio Monforte, E Fontas, SW Worm, O Kirk, A Phillips, CA Sabin, JD Lundgren, M Law, and the D:A:D Study Group.
Poster 808 as pdf file 191 KB
2 Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) that the sum of its components; Data from the D:A:D study. SW Worm, CA Sabin, P Reiss, W El-Sadr, A D´Arminio Monforte, C Pradier, R Thiebaut, M Law, M Rickenback, S de Wit, JD Lundgren, N Friis-Møller and the D:A:D Study Group
Poster 815 as pdf file 113 KB
3 Underutilization of recommended interventions for prevention of cardiovascular (CV) disease in HIV-infected patients with established CV disease or diabetes. CA Sabin, R Weber, F Dabis, P Reiss, S de Wit, W El-Sadr, A D´Arminio Monforte, M Law, O Kirk, SW Worm , N Friis-Møller, JD Lundgren, and the D:A:D Study Group.
Poster 816 as pdf file 118 KB
4 Detection of chronic renal failure (CRF) amon HIV-patients within the EuroSIDA Study. A Mocroft, O Kirk, J Gatell, P Reiss, P Gargalianos, K Zilmer, M Beniowski, JP Viard, S Staszewski, JD Lundgren for the EuroSIDA Study Group.
Poster 828 as pdf file 106 KB
5 Normalisation of CD4 count in HIV-infected patients with maximal virological suppression (<50 copies/ml) taking combination antiretroviral therapy. A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, G Fätkenheuer, JD Lundgren for the EuroSIDA Study Group
Poster 519 as pdf file 100 KB
6 Predicted risk of coronary heart disease (CHD) with Tipranavir exposure compared to conventional PI in the RESIST trial. N Friis-Møller, M Kraft, H Valdez, D Hall, and JD Lundgren.
Poster 809 as pdf file 122 KB
Updated: 30 Nov 2007